ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0844

Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort

Manouk de Hooge1, Rosalinde Stal2, Alexandre Sepriano3, Xenofon Baraliakos4, Monique Reijnierse5, Juergen Braun6, Désirée van der Heijde7, Floris Van Gaalen2 and Sofia Ramiro7, 1Ghent University Hospital, Hesperange, Luxembourg, 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 3Leiden University Medical Centre, Portela Loures, Portugal, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Leiden University Medical Center, Leiden, Netherlands, 6Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Back pain, Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: To assess whether posterior element (PE) inflammation, in particular in the facet joints (FJ), is associated with new facet joint ankylosis on MRI one year later, in patients with radiographic axial spondyloarthritis (r-axSpA).

Methods: Patients with an r-axSpA diagnosis recruited from Germany (Herne) and the Netherlands (Leiden) were included in the Sensitive Imaging in Ankylosing Spondylitis (SIAS) observational cohort when all following criteria were met: 1) presenting with ≥1 inflammatory lesion on MRI-spine according to SPondyloArthritis Research Consortium of Canada score, 2) presenting with 1-18 syndesmophytes (assessed with modified Stoke Ankylosing Spondylitis Spinal Score), and 3) fulfilling the modified New York criteria. Spinal MRIs were performed at baseline, after 1 year and after 2 years. PE inflammatory lesions and facet joint ankylosis were assessed on MRI, per vertebral unit level (VU) by 3 readers independently. FJ inflammation in the cervical spine was not assessed. With conditional probability tables the probability of developing facet joint ankylosis after one year was described. Multilevel time-lagged auto-regressive GEE was used for the association between PE (or FJ) inflammation and the development of facet joint ankylosis one year later, taking the reader and VU levels into account.

Results: In 58 patients MRI data of at least 2 readers was available. Their average age was 49±10 years and 85% was male. Inflammation in the PE or FJ at baseline was seen in 34 (58.6%) and 14 (24.1%) patients respectively. PE inflammation was distributed throughout the whole spine but emphatically more prevalent in the lower part of the thoracic spine (8.6%-15.5%). FJ inflammation was infrequently present, it was more often reported in the higher thoracic segment of the spine (1.7%-5.2%) (heatmap). Facet joint ankylosis was reported in 15 patients (25.9%) at baseline and in 17 patients (29.3%) with follow up visits. Facet joint ankylosis was mainly present in the upper half of the spine (heatmap). In 19 patients (32.8%) the development of new facet joint ankylosis over 1 or 2 years was seen by at least 1 reader.

Of the VU levels with PE or FJ inflammation only very few showed new facet joint ankylosis after one year; 2 and 1 VU levels, respectively (table). There was no association between PE inflammation and the development of new facet joint ankylosis in the same level after one year (OR=1.15, 95%CI 0.55-2.42). However, FJ inflammation was associated with the development new facet joint ankylosis one year later (OR=3.79, 95%CI 1.47-9.75).

Conclusion: PE inflammation and facet joint ankylosis on MRI were uncommonly present in r-axSpA patients. No association was found between inflammation in the PE and the development of facet joint ankylosis. However, when inflammation in the FJ is present the likelihood of developing facet joint ankylosis after 1 year is over 3 times higher compared to FJ without inflammation. This finding adds to the pathophysiological relationship between inflammation and damage at the same anatomical location.

Supporting image 1

The extent of posterior element lesions on MRI across the 23 vertebral units (VU) in radiographic axial spondyloarthritis patients with 2 years follow-up.

Supporting image 2

Table. Probability of developing facet joint ankylosis with and without posterior element inflammation present one year before, in r-axSpA patients from the SIAS cohort. PE; posterior elements, *; number of VU levels with inflammation in at least 1 part of the posterior elements (pedicle, facet joint, processes spinosi, soft tissue), #; number of facet joints, FJ; facet joint, P; probability


Disclosures: M. de Hooge: UCB, 6; R. Stal: None; A. Sepriano: None; X. Baraliakos: AbbVie, 2, 6, BMS, 2, 6, Chugai, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer Inc, 2, 6, UCB, 2, 6; M. Reijnierse: None; J. Braun: None; D. van der Heijde: AbbVie, 2, Bayer, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, GSK, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; F. Van Gaalen: AbbVie, 12, Personal fees, BMS, 12, Personal fees, Eli Lilly, 12, Personal fees, Jacobus Stichting, 5, MSD, 12, Personal fees, Novartis, 5, 12, Fees, Stichting ASAS, 5, Stichting Vrienden van Sole Mio, 5, UCB Pharma, 5; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, Galapagos, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, UCB Pharma, 2, 5.

To cite this abstract in AMA style:

de Hooge M, Stal R, Sepriano A, Baraliakos X, Reijnierse M, Braun J, van der Heijde D, Van Gaalen F, Ramiro S. Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/facet-joint-inflammation-is-rare-but-when-present-it-is-associated-with-facet-joint-ankylosis-in-radiographic-axial-spondyloarthritis-patients-from-the-sias-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facet-joint-inflammation-is-rare-but-when-present-it-is-associated-with-facet-joint-ankylosis-in-radiographic-axial-spondyloarthritis-patients-from-the-sias-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology